Sol-Gel Technologies Ltd SLGL

$68.71 -0.79 (-1.14%)

Valuation

Market cap
223,614,000
Revenue TTM
$19,390,000
Net income TTM
$-6,130,000
PE ratio
0.00
Forward PE
—
Profit margin
-31.61%
Debt to equity
0.00

Trading

Volume
16,413
Avg volume
55,464
Day's range
$67.51 – $70.00
Shares out
3,274,000
Stochastic %K
23%
Beta
1.14
Analysts
Strong Sell
Price target
$147.00

Price

Company profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustula...

Show more

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 8 931 3433
Website
https://www.sol-gel.com
Address
7 Golda Meir Street, Weizmann Science Park, Ness Ziona, Israel

Latest news

Stocktwits

Ace_AP Oct 9, 2:07 AM
$SLGL dip down to $66 crazy
0 replies
mktrdr59 Sep 22, 1:21 AM
$SLGL at/near measured move price projection. Making lower price low, but staying above lower BB.
0 replies
weichsel1 Sep 16, 6:25 PM
$SLGL It would appear that a shareholder is slowly selling off a substantial position based on knowledge or fear of the November announcement of the clinical trial results. (I presume if the results were good news they would have been announced sooner). No other reason why the company is now worth 30 poercent less than it was 45 days ago.
1 replies
frontiere Aug 24, 9:10 AM
$SLGL Sol-Gel ref=$77 closing price — No pstn of this tight float, low borrow avail, no options old shitco , and I don’t intend to initiate a pstn — but here’s a good succinct bearish 🚩 writeup — just posting a warning for any longs into Nov 2026 Ph3 readout https://riskinhibitor.substack.com/p/slgl-zero
0 replies
weichsel1 Aug 14, 2:47 AM
$SLGL any comments on the recent volatility?
0 replies
weichsel1 Aug 11, 9:14 PM
$SLGL Any reason for the substantial drop today? I see an update in the primary drug trial, posted by FDA_tracker, but I do not see any actual news regarding the trial. Note that the trial is scheduled to complete in October - so we are closing on the final and exciting news!
0 replies
fda_tracker Aug 10, 3:42 PM
$SLGL Phase 3 trial w/est Aug completion date NCT06050122: https://www.clinicaltrials.gov/study/NCT06050122 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 replies
tradehulk Jul 22, 3:22 PM
$SLGL 🚨$CHAI about to trade 50M shares premarket! 💥
0 replies